Tesaro and its new med Zejula are on the block, but bidders aren't rushing in: WSJ
admin 1st June 2017 Uncategorised 0Ahead of the year’s biggest cancer-data download, closely watched maker of oncology drugs Tesaro has put itself up for sale, the WSJ reports. Thanks to its blockbuster-to-be PARP inhibitor Zejula, Tesaro could sell for $9 billion-plus—if it does at all, that is.
More: Tesaro and its new med Zejula are on the block, but bidders aren't rushing in: WSJ
Source: fierce